Inside informationEnglish
Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 10/09/2025, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 117069_20250910